v3.26.1
Segment Reporting
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting

Note 12. Segment Reporting

The Company operates and manages its business as one reportable and operating segment. The determination of a single operating segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (the “CODM”). The Company's chief executive officer, who is the CODM, assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the statements of operations and comprehensive loss. The monitoring of budgeted versus actual results are used in assessing performance of the segment, and making operating decisions, allocating resources, and planning and forecasting for future periods. The measure of segment assets is reported on the balance sheets as total assets.

In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses:

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

External research and development expenses:

 

 

 

 

 

 

Clinical trials expenses

 

$

755

 

 

$

528

 

Consulting and outside services

 

 

748

 

 

 

632

 

Other external research and development (1)

 

 

2,442

 

 

 

3,960

 

Total external research and development expenses

 

 

3,945

 

 

 

5,120

 

 

 

 

 

 

 

 

Internal research and development expenses:

 

 

 

 

 

 

Personnel related expenses

 

 

2,798

 

 

 

2,570

 

Total research and development expenses

 

$

6,743

 

 

$

7,690

 

 

(1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.